• 1
    1993 Revised Classification System for HIV Infection and Expanded Surveillance of Definition for AIDS Among Adolescents and Adults. MMWR Recomm Rep 1992; 31: 119.
  • 2
    Karon JM, Rosenberg PS, McQuillan G, Khare M, Gwinn M, Peterson LR. Prevalence of HIV infection in the United States. JAMA 1996; 276: 126131.
  • 3
    Enger C, Graham N, Peng Y, Chmiel JS, Kingsley LA, Detels R, Munoz A. Survival from early, intermediate, and late stages of HIV infection. JAMA 1996; 275: 13291334.
  • 4
    Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996; 124: 654663.
  • 5
    Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946954.
  • 6
    Stevenson M. Viral genes and their products. In MeriganTC, BartlettJG, BolognesiD, eds. Textbook of AIDS Medicine, 2nd ed. pp. 13-48, Baltimore: Williams & Wilkins; 2001; 13–48.
  • 7
    Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117122.
  • 8
    Buchbinder SP, Katz MH, Hessol, NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. AIDS 1995; 8: 11231128.
  • 9
    Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209216.
  • 10
    Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996; 335: 10811090.
  • 11
    Tavel JA, Miller KD, Masur H. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: Protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Clin Infect Dis 1999; 28: 643676.
  • 12
    Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 1726.
  • 13
    Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853860.
  • 14
    Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725733.
  • 15
    Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112116.
  • 16
    Karpas A, Lowdell M, Jacobson SK, Hill F. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK506. Proc Natl Acad Sci U S A 1992; 89: 83518355.
  • 17
    Martin LN, Murphey-Corb M, Mack P, Baskin GB, Pantaleo G, Vaccarezza M, et al. Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys. J Infect Dis 1997; 176: 374383.
  • 18
    Andrieu JM, Even P, Venet A, Tourani JM, Stern M, Lowenstein W, et al. Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease. Clin Immunol Immunopathol 1988; 47: 181198.
  • 19
    Levy R, Jais JP, Tourani JM, Even P, Andrieu JM. Long-term follow-up of HIV positive asymptomatic patients having received cyclosporin A. Adv Exp Med Biol 1995; 374: 229234.
  • 20
    Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999; 21: 362370.
  • 21
    Chapuis AG, Paolo Rizzardi G, D'Agostino C, Attinger A, Knabenhans C, Fleury S, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000; 6: 762768.
  • 22
    Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288: 199206.
  • 23
    Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): The effect of coinfection on survival. Clin Infect Dis 1999; 29: 150154.
  • 24
    Rusti V, Hoofnagle J, Gerin J. Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101: 795797.
  • 25
    Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183: 11121115.
  • 26
    Eyster ME, Sherman KE, Goedert JJ, Katsoulidou A, Hatzakis A. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6: 602610.
  • 27
    Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV infected patients. Prevalence and prognostic value. J Hepatol 1997; 27: 1824.
  • 28
    Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 15.
  • 29
    Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, Yoffe B. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240247.
  • 30
    Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J. Hepatitis C and HIV infection: Biological, clinical, and therapeutic implications. J Hepatol 1999; 31( suppl 1): 119123.
  • 31
    Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-497.
  • 32
    Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15: 14.
  • 33
    Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al. Mortality from liver disease in patients with HIV infection: A cohort study. J Acquir Immune Defic Syndr 2000; 24: 211217.
  • 34
    Gordon S, Reddy R, Gould E. The spectrum of liver disease in the acquired immunodeficiency syndrome. J Hepatol 1986; 2: 475484.
  • 35
    Carr A, Morey A, Mallon P, Williams D, Thorburn DR. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 2001; 357: 14121414.
  • 36
    Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999; 30: 156160.
  • 37
    Walker UA, Bauerle J, Laguno M, Murillas J, Mauss S, Schmutz G, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39: 311317.
  • 38
    Ena J, Amador C, Benito C, Fenoll V, Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine- and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS 2003; 14: 776781.
  • 39
    Bouche H, Housset C, Dumont JL, Carnot F, Menu Y, Aveline B, et al. AIDS-related cholangitis: Diagnostic features and course in 15 patients. J Hepatol 1993; 17: 3439.
  • 40
    Pol S, Romana CA, Richard S, Amouyal P, Desportes-Livage I, Carnot F, et al. Microsporidia infection in patients with the human immunodeficiency virus and unexplained cholangitis. N Engl J Med 1993; 328: 9599.
  • 41
    Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev 2002; 1: 329337.
  • 42
    Mason AL, Xu L, Guo I, Munoz S, Jaspan JB, Bryer-Ash M, et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998; 351: 16201624.
  • 43
    Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? Transplantation 1998; 65: 11871191.
  • 44
    Phillips A, Wainberg MA, Coates R, Klein M, Rachlis A, Read S, et al. Cyclosporine-induced deterioration in patients with AIDS. Can Med Assoc J 1989; 140: 14561460.
  • 45
    Baum KF. Immunosuppression in HIV-infected transplant recipients. Clin Infect Dis 1992; 14: 622623.
  • 46
    Schwarz A., Offermann G, Keller F, Bennhold I, L'age-Stehr J, Krause PH, Mihatsch MJ: The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation—data on four cases and review of the literature. Transplantation 1993; 55: 95103.
  • 47
    Dummer JS, Erb S, Breinig MK, Ho M, Rinaldo CR Jr, Gupta P, et al. Infection with human immunodeficiency virus in the Pittsburgh transplant population. A study of 583 donors and 1043 recipients, 1981-1986. Transplantation 1989; 47: 134140.
  • 48
    Tzakis AG, Cooper MH, Dummer JS, Ragni M, Ward JW, Starzl TE. Transplantation in HIV+ patients. Transplantation 1990; 49: 354358.
  • 49
    Fung JJ. Transplantation in HIV-positive patients? Medscape Ask the Experts. Available at Accessed February 29, 2000.
  • 50
    Ragni MV, Bontempo FA, Lewis JH. Organ transplantation in HIV-positive patients with hemophilia. N Engl J Med 1990; 322: 18861887.
  • 51
    Erice A, Rhame FS, Heussner RC, Dunn DL, Balfour HH Jr. Human immunodeficiency virus infection in patients with solid-organ transplants: Report of five cases and review. Rev Infect Dis 1991; 13: 537547.
  • 52
    Jacobson SK, Calne RY, Wreghitt TG. Outcome of HIV infection in transplant patient on cyclosporin [letter]. Lancet 1991; 337: 794.
  • 53
    Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42: 744749.
  • 54
    Vanhems P, Bresson-Hadni S, Vuitton DA, Miguet JP, Gillet M, Lab M, Brechot C. Long-term survival without immunosuppression in HIV-positive liver-graft recipients. Lancet 1991; 337: 126.
  • 55
    Kuo PC, Stock PG. Transplantation in the HIV+ patient. Am J Transplant 2001; 1: 1317.
  • 56
    Samuel D, Duclos Vallee JC, Teicher E, Vittecoq D. Liver transplantation in patients with HIV infection. J Hepatol 2003; 39: 36.
  • 57
    Roland M, Lo B, Braff B, Stock PG. Key clinical, ethical, and policy issues in the evaluation of the safety and efficacy of solid organ transplantation in HIV-infected patients. Arch Intern Med 2003; 163: 17731778.
  • 58
    McCarthy M, Gane E, Pereira S, Tibbs CJ, Heaton N, Rela M, et al. Liver transplantation for haemophiliacs with hepatitis C cirrhosis. Gut 1996; 39: 870875.
  • 59
    Caccamo L, Colledan M, Rossi G, Gridelli B, Maggi U, Vannelli A, et al. Post-transplant primary disease does not influence 6-year survival after liver transplantation beyond 1 year. Transpl Int 1998; 11( suppl 1): S212S220.
  • 60
    Ragni MV, Dodson SF, Hunt SC, Bontempo FA, Fung JJ. Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome. Blood 1999; 93: 11131114.
  • 61
    Sheikh AM, Wolf DC, Lebovics E, Goldberg R, Horowitz HW. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999; 68: 307309.
  • 62
    Schvarcz R, Rudbeck G, Soderdahl G, Stahle L. Interaction between nelfinavir and tacrolimus after orthotopic liver transplantation in a patient coinfected with HIV and Hepatiitis C virus (HCV). Transplantation 2000; 69: 21942195.
  • 63
    Schliefer K, Paar WD, Aydemir G, Wolff M, Rockstroh JK, Spengler U, Sauderbruch T. Orthotopic liver transplantation in a 33-year-old patient with fulminant hepatitis B and HIV infection. Dtsch Med Wochenschr 2000; 125: 523526.
  • 64
    Prachalias A, Anton P, Taylor C, Srinivasan P, Muiesan P, Wendon J, et al. Liver transplantation in adults coinfected with HIV. Transplantation 2001; 72: 16841688.
  • 65
    Ragni M, Belle SH, Im KA, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 14121420.
  • 66
    Gow PJ, Mutimer D. Liver transplantation for an HIV-positive patient in the era of highly active antiretroviral therapy. AIDS 2001; 15: 291292.
  • 67
    Tolan DJ, Davies MH, Millson CE. Fibrosing cholestatic hepatitis after liver transplantation in a patient with Hepatitis C and HIV infection [letter]. N Engl J Med 2001; 345: 1781.
  • 68
    Sugawara Y, Ohkubo T, Makuuchi M, Kimura S, Morisawa Y, Tachikawa N, Oka S. Living donor liver transplantation in an HIV-positive patient with hemophilia. Transplantation 2002; 74: 16551656.
  • 69
    Rafecas A, Rufi G, Fabregat J, Xiol X. Liver transplantation in a patient infected by human immunodeficiency virus. Med Clin (Barc) 2002; 119: 596.
  • 70
    Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239247.
  • 71
    Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: A pilot safety and efficacy study. Transplantation 2003; 76: 370375.
  • 72
    Gonzalez Alonso R, Barcena R, Blesa C, Garcia M, Moreno A, Fortun J, et al. Liver transplantation in a patient coinfected with human immunodeficiency virus and hepatitis C virus. Transplant Proc 2003; 35: 18461847.
  • 73
    Nowak P, Schvarcz R, Ericzon BG, Flamhole L, Sonnerborg A. Follow-up of a antiretroviral treatment in liver transplant recipients with primary and chronic HIV type 1 infection. AIDS Res Hum Retroviruses 2003; 19: 1319.
  • 74
    Jeng LB, Lee WC, Hung CM, Yu MC, Kuo LM, Chen MF. Liver transplantation in a patient with human immunodeficiency virus infection: A case report. Transplant Proc 2003; 35: 361.
  • 75
    Boschetto A, Ettorre GM, Durand F, Dondero F, Francoz C, Soommacale D, et al. Is anti-retroviral treatment after transplantation in HIV positive patients always necessary? [abstract no. 14]. 10th Congress of the International Liver Transplantation Society, Kyoto, Japan, 10 June 2004. Liver Transpl 2004; 10: C6.
  • 76
    Roland M, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003; 75: 425429.
  • 77
    Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520525.
  • 78
    Berenger M, Forman LM, Lewis JD, Berlin HA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 79
    Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32: 673684.
  • 80
    Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993; 73: 10671078.
  • 81
    Bartz SR, Hohenwalter E, Hu MK, Rich DH, Malkovsky M. Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc Natl Acad Sci U S A 1995; 92: 53815385.
  • 82
    Mlynar E, Bevec D, Billich A, Rosenwirth B, Steinkasserer A. The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells. J Gen Virol 1997; 78: 825835.
  • 83
    Calabrese LH, Lederman MM, Spritzler J, Coombs RW, Rox L, Schock B, et al. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: Implications for solid organ transplantation. J Acquir Immune Defic Syndr 2002; 29: 356362.
  • 84
    Bouscarat F, Samuel D, Simon F, Debat P, Bismuth H, Saimot AG. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. Clin Infect Dis 1994; 19: 854859.
  • 85
    McComsey GA, Whalen CC, Mawhorter SD, Asaad R, Valdez H, Patki AH, et al. Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 2001; 15: 321327.
  • 86
    Wallis RS, Kalayjian R, Jacobson JM, Fox L, Purdue L, Shikuma CM, et al. A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm3. J Acquir Immune Defic Syndr 2003; 32: 281286.
  • 87
    Coull JJ, Turner D, Melby T, Betts MR, Lanier R, Margolis DM. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2001; 26: 423434.
  • 88
    Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983; 309: 453458.
  • 89
    Shirai A, Cosentino M, Leiitman-Klinman SF, Klinman DM. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest 1992; 89: 561566.
  • 90
    Hirose K, Baxter-Lowe LA, Carlson L, Freise CE, Hirose R, Cunniffe K, et al. Unexpectedly high rejection rates in HIV-positive recipients of renal transplants [abstract no. 481]. 2004 American Transplant Congress, Boston, MA, 16 May 2004. Am J Transplant 2004; 4( suppl 8): 290
  • 91
    Toso C, Berney T, Oberholzer J, Chave JP, Martin PPY, Zeender E, et al. Kidney-pancreas transplantation in a long-term non-progressor HIV-infected recipient. Am J Transplant 2003; 3: 631633.
  • 92
    Purgus R, Tamalet C, Poignard P, Spire B, George F, Robert A, Olmer M. Long-term nonprogressive human immunodeficiency virus-1 infection in a kidney allograft recipient. Transplantation 1998; 66: 13841386.
  • 93
    Jain AB, Venkataramanan R, Shapiro R, Scantlebury V, Potdar S, Bonham A, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8: 841845.
  • 94
    Jain AB, Venkataramanan R, Eghtesad B, Marcos A, Ragni M, Shapiro R, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 2003; 9: 954960.
  • 95
    Antonini M, Ettorre GM, Vennarecci G, D'Offizi G, Narciso P, Del Non F, et al. Anti-retrovirals and immunosuppressive drug interactions in a HIV-positive patient after liver transplantation. Hepatogastroenterology 2004; 51: 646648.
  • 96
    Brinkman K, Huysmans F, Burger DM. Pharmacokinetic interaction between saquinavir and cyclosporine [letter]. Ann Intern Med 1998; 129: 914915.
  • 97
    Jain AK, Venkataramanan R, Fridell JA, Gadomski M, Shaw LM, Ragni M, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: A case report. Liver Transpl 2002; 8: 838840.
  • 98
    Antoniades C, Macdonald C, Knisely A, Taylor C, Norris S. Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient. Liver Transpl 2004; 10: 699702.
  • 99
    Kusne S, Shapiro R, Fung J. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis 1999; 1: 187203.
  • 100
    McGavin JK, Goa KL. Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001; 61: 11531183.
  • 101
    Price P, Mathiot N, Krueger R, Stone S, Keane NM, French MA. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J Clin Virol 2001; 22: 279287, 2001.
  • 102
    Gow PJ, Pillay D, Mutimer D. Solid organ transplantation in patients with HIV infection. Transplantation 2001; 72: 177181.
  • 103
    Gomez E, Aguado S, Rodriguez M, Alvarez-Grande J. Kaposi's sarcoma after renal transplantation—disappearance after reduction of immunosuppression and reappearance 7 years later after start of mycophenolate mofetil treatment. Nephrol Dial Transplant 1998; 13: 32793280.
  • 104
    Doutrelepont JM, De Pauw L, Gruber SA, Dunn DL, Qunibi W, Kinnaert P, et al. Renal transplantation exposes patients with previous Kaposi's sarcoma to a high risk of recurrence. Transplantation 1996; 62: 463466.
  • 105
    den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 28952902.
  • 106
    McGovern B, Bica I. Risk of HAART therapy in hepatitis C. Hepatology 2002; 35: 730.
  • 107
    Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004; 5: 16331639.
  • 108
    Ahuja TS, Zingman B, Glicklich D. Long-term survival in an HIV-infected renal transplant recipient. Am J Nephrol 1997; 17: 480482.
  • 109
    Swanson SJ, Kirk AD, Ko CW, Jones CA, Agodoa LY, Abbott KC. Impact of HIV seropositivity on graft and patient survival after cadaveric renal transplantation in the United States in the pre highly active antiretroviral therapy (HAART) era: An historical cohort analysis of the United States Renal Data System. Transpl Infect Dis 2002; 4: 144147.
  • 110
    Calabrese LH, Albrecht M, Young J, McCarthy P, Haug M, Jarcho J, Zackin R. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 2003; 348: 23232328.
  • 111
    Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002; 347: 284287.